Overview of Minra

Property	Description
Active Ingredients	Brompheniramine Maleate, Phenylephrine Hydrochloride
Pharmacological Class	Antihistamine/Nasal Decongestant Combination
Common Use	Integrated relief of congestion and upper respiratory symptoms
Route of Administration	Oral
Origin	Synthetic

Minra is formally classified as a synthetic, fixed combination medication belonging to the Antihistamine/Nasal Decongestant Combination drug class. This preparation combines two distinct active pharmaceutical ingredients to address a complex range of symptoms simultaneously. The design of this dual compound provides combined therapeutic action on both allergy and congestion pathways. This product is intended to provide simultaneous relief from congestion and histamine-related symptoms.

The essential composition of Minra comprises two synthesized compounds: Brompheniramine Maleate and Phenylephrine Hydrochloride. Brompheniramine Maleate is classified as a first-generation alkylamine antihistamine, while Phenylephrine Hydrochloride is a direct-acting sympathomimetic amine decongestant. The medication is formulated for oral administration and is typically available in forms such as oral liquid (solution or suspension), tablets, or extended-release capsules. This formulation is frequently marketed toward the relief of persistent symptoms that accompany conditions like hay fever.

The general purpose of Minra is to provide integrated symptomatic relief from the congestion and irritation associated with allergic conditions and upper respiratory discomfort. The combination leverages the effects of its components: the antihistamine works to help counteract the effects of histamine and dry up excess secretions, while the decongestant reduces the swelling of blood vessels in the nasal passages. This dual mechanism is utilized to target multiple symptoms, including sneezing, watery eyes, runny nose, and nasal or sinus pressure resulting from conditions like allergic rhinitis or the common cold. The combined use of these classes is intended to provide enhanced symptomatic relief compared to monotherapy.

Regulatory References

EMA Public Assessment Report: Desloratadine/Pseudoephedrine Combination

What side effects are possible with Minra?

Possible Side Effects and Safety Information

Adverse reaction documentation for Minra, a fixed-combination antihistamine and decongestant, is structured by frequency and affected body systems as defined in regulatory materials.

Adverse Reaction Scope

Category	Documented Effects/Classification
Common Side Effects	Drowsiness, sedation, weariness, dry mouth, dry nose, dry throat, headache, and upset stomach (nausea).
System-Organ Classes	Effects are listed across the Nervous System (e.g., dizziness, confusion, excitation), Gastrointestinal System (e.g., constipation, dry mouth), Ocular System (e.g., blurred vision, seeing halos), and Cardiovascular System (e.g., palpitations, increased blood pressure).
Serious Adverse Reactions	Reactions documented as rare but potentially severe include anaphylactic shock, seizures, dangerously high blood pressure (hypertensive crisis), and certain hematologic disorders (e.g., agranulocytosis).

Regulatory Safety Notes

The official label mandates specific safety constraints and population-based considerations:

Safety Restrictions: The medication is strictly contraindicated for use in patients taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping MAOI therapy. Use is also restricted in individuals with pre-existing conditions such as severe hypertension, narrow-angle glaucoma, or severe coronary artery disease.
Population-Specific Caution: Specific notes exist for older adults, who may be more susceptible to CNS side effects like dizziness and confusion. In children, the drug may paradoxically cause excitation or agitation instead of drowsiness. Use during pregnancy or lactation is advised against due to documented risks.
Exposure Patterns: Regulatory text advises against using the medication for periods longer than 7 days to avoid masking signs of a serious underlying condition.

The official safety information structures the understanding of Minra's risks by explicitly classifying adverse reactions by system and frequency. This framework defines the medicine’s limitations by identifying absolute contraindications and listing conditions and populations that require specific caution as mandated by regulatory authorities.

Overdose and Emergency Response

The Minra overdose profile is defined by the combined toxicity of its antihistamine and sympathomimetic components, leading to severe and life-threatening outcomes. Officially documented overdose presentations span the Central Nervous System and Cardiovascular System.

Manifestations can include a dual pattern of CNS effects: from stimulation (e.g., excitability, nervousness, hallucinations, seizures) to profound depression (e.g., lethargy and coma). Cardiovascular toxicity is marked by tachycardia, hypertension, and serious cardiac arrhythmias.

Severe outcomes documented in regulatory literature, particularly in infants and small children, include an elevated risk of convulsions and death. The official instruction for overdosage is explicit due to this severity classification: patients must seek emergency medical attention or contact a Poison Control Center right away.

Overdose management procedures described in official documents are symptomatic and supportive, and may involve interventions such as gastric lavage, administration of activated charcoal, and essential cardiac monitoring to manage the systemic effects. This framework defines the official, high-risk context of Minra overdosage.

Therapeutic Uses of Minra

What Minra Treats: Main Uses and Benefits

Minra is applied across domains where additional symptomatic support is needed in conditions involving acute or disruptive symptom patterns from upper respiratory allergies and the common cold. It is commonly used across conditions characterized by periods of heightened symptoms.

A key therapeutic focus is to offer integrated relief when multiple symptoms occur together, often during phases when symptoms become more noticeable due to seasonal changes or acute illness. It is relevant for easing symptom clusters that may become intense or disruptive, including sneezing, runny nose, itchy, watery eyes, and nasal stuffiness.

Quick Fact

Quick Fact: Symptomatic Relief

This medication is applied in scenarios where additional management of discomfort is required, assisting with the overall ease of temporary functional strain caused by congestion and irritation.

Regulatory References

U.S. National Library of Medicine’s DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Minra? — Official Regulatory Information

The eligibility profile for Minra is strictly defined by government regulatory documents, delineating populations for whom use is permitted, restricted, or absolutely prohibited.

Eligibility Scope

Populations for whom use is allowed: Adults and children 12 years of age and over. Use is permitted for children 6 to 11 years of age, but is subject to restrictions outlined in the labeling.

Populations for whom use is contraindicated: Minra is strictly contraindicated for patients with severe hypertension, severe coronary artery disease, or a known hypersensitivity to the ingredients. Use is also prohibited in newborn or premature infants and nursing mothers.

Age and Condition-Specific Eligibility Rules

Age-related eligibility: Standard use is established for adults and adolescents aged 12 years and older. Use in children under 6 years is generally not recommended in regulatory labeling, and the medicine is not to be given to children under 2 years. Older adults (65 years and over) may experience increased sensitivity, classifying their use as conditional.

Condition-specific eligibility: Use is conditional for individuals with pre-existing conditions such as glaucoma, diabetes mellitus, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

Eligibility-related restrictions: Minra is absolutely contraindicated for anyone who has taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. The product is also explicitly prohibited from being used for the purpose of sedating a child.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Minra (Brompheniramine Maleate / Phenylephrine Hydrochloride) detail interactions governed by pharmacodynamic effects.

Interaction Scope

The profile identifies the following categories with documented interaction patterns: Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Sympathomimetic Agents, Tricyclic Antidepressants, Beta-Adrenergic Blocking Drugs, and Cardiac Glycosides. The most critical interaction involves MAOIs, which are explicitly prohibited from co-administration. This restriction is based on the mechanism of MAOIs intensifying the antihistamine’s anticholinergic effects and enhancing the pressor activity of the decongestant. This combination requires a mandatory 14-day separation period after the MAOI is discontinued.

Interaction Classifications (High-Level)

The interaction with MAOIs is categorized as a Contraindicated Combination. Other interactions are classified as Use-with-Caution/Avoidance due to additive effects.

Resulting Interaction Structure

Official regulatory statements indicate that Alcohol and other CNS Depressants must be avoided due to the risk of additive sedative effects. Co-administration with TCAs, Beta-Adrenergic Blockers, or other Sympathomimetic Amines may increase cardiovascular risk or reduce the effectiveness of antihypertensive drugs. Furthermore, the product is contraindicated for use in newborns, premature infants, and nursing mothers.

These constraints define the interaction structure primarily through prohibited combinations and additive pharmacodynamic effects rather than complex metabolic changes.

Mechanism of Action

How Minra Works

Minra is classified as a bisphosphonate that works by selectively accumulating in the mineralized bone matrix and becoming internalized by bone-resorbing cells (osteoclasts). Once inside the osteoclast, Minra blocks a specific molecular target integral to the regulation of bone remodeling.

Intracellular Signaling Cascade

Minra non-hydrolyzably binds to and inhibits the enzyme Farnesyl Pyrophosphate Synthase (FPPS) within the mevalonate pathway. Inhibition of FPPS prevents the post-translational prenylation of small GTPase signaling proteins, such as Rac and Rho. These prenylated proteins are essential regulators of the osteoclast cytoskeleton and internal function. This disruption immediately impairs the osteoclast's ability to form a ruffled border and adhere to the bone surface, effectively initiating osteoclast dysfunction.

Physiological Consequence

The resulting loss of osteoclast cytoskeletal integrity and function leads to a decrease in the overall rate of bone matrix breakdown (resorption). This pharmacological action maintains the structural balance of bone turnover by shifting the net activity toward the formation-dominant phase by osteoblasts.

Dosage and Administration Information

The administration of Minra, a fixed combination of Brompheniramine Maleate and Phenylephrine Hydrochloride, is based on specific parameters. The medication is formulated for oral administration and is typically available as an immediate-release tablet or an oral liquid solution.

The dosing regimen is standardized based on age. For adults and adolescents 12 years and older, the dose is one unit (such as one tablet or 20 mL of the standard liquid formulation). This dose is repeated every 4 hours. Pediatric patients ages 6 to under 12 years are directed to receive one-half the adult unit dose, such as 10 mL of the liquid, following the same 4-hour interval. Intake is limited to a maximum of 6 doses within any 24-hour period.

Administration Rule	Requirement
Administration Route	Oral, as either tablet or liquid solution.
Frequency and Timing	Every 4 hours; maximum 6 doses in 24 hours.
Duration Constraint	Intended for short-term use; stop if symptoms persist longer than 7 days.
Procedural Condition	Liquid solutions must be measured using only the calibrated device provided with the product.

The medication can be taken with or without food. Use in children under the age of 6 requires professional direction. These parameters provide a standardized, time-limited approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Minra

Evidence for Use in Acute Upper Respiratory Symptoms (e.g., Common Cold)

This section summarizes the systematic reviews and randomized controlled trials (RCTs) used in research exploring symptom variability and patterns during a common cold episode. Research has examined the combination of Brompheniramine and Phenylephrine in studies focusing on episodes where symptoms become more noticeable, such as sneezing, a runny nose (rhinorrhea), and nasal congestion.

Studies have focused primarily on short-term symptom changes in populations of adults and older children (typically those age 6 and older), with treatment periods lasting up to 10 days. Findings describe patterns observed in the studies related to outcomes capturing phases of heightened symptom activity, such as overall discomfort reported by patients. Findings were often described as mixed or limited when assessing patterns related to specific, individual cold symptoms.

Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

Research has explored the combination's relevance in trials assessing short-term or episodic symptom patterns linked to inflammatory or irritative states, such as Seasonal Allergic Rhinitis (SAR). Studies explored patient-reported outcomes describing perceived discomfort related to symptoms like nasal congestion and a runny nose in populations primarily consisting of adults with confirmed SAR.

Research examined the combination compared with antihistamine monotherapy and measured composite nasal symptoms. Trials typically monitored responses over defined time intervals, with follow-up durations often being very short—for example, a few hours after a single dose. These studies contribute to the broader evidence landscape by helping contextualize how patients reported their experience during periods of heightened symptom activity.

What Research Evidence Remains Uncertain about Minra

One key area of ongoing scientific discussion relates to the Phenylephrine component (the nasal decongestant). Research is ongoing, and the certainty remains low regarding how the Phenylephrine component is assessed in research related to nasal congestion when administered orally.

Furthermore, the short follow-up durations were limited, meaning long-term outcomes are not fully established, and there is limited information about the overall evolution of symptom changes over longer periods. Data for certain groups, such as very young children (under 6 years old), also remain insufficient from structured research.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Minra (FAQ)

Q: Can Minra be taken with common over-the-counter pain relievers?

Regulatory documentation detailing Minra's interactions focuses on specific regulated drug classes. The label generally warns against taking the product with other medications that contain a decongestant or a stimulant. Regulatory warnings indicate that you should inform your healthcare provider about all medications you take, which may include over-the-counter pain relievers or cold remedies.

Q: Are there any specific foods or drinks that should be avoided while taking Minra?

Regulatory warnings state that alcohol should be avoided because it may increase the feeling of drowsiness caused by Minra. Regarding food, official product information indicates that the medication may be taken with or without food, as there are no specific food restrictions listed.

Q: Is Minra safe for use by older adults?

Official documents note that older adults may experience increased sensitivity to this medicine. This population may be more likely to experience certain central nervous system side effects, such as dizziness and confusion. The official documentation includes specific caution notes for use in older adults due to these potential effects.

Q: Does Minra interact with supplements like vitamins or herbal remedies?

The official product label primarily addresses interactions with regulated pharmaceutical drugs. The label also includes a warning against taking the product with other items that may have stimulant properties. Official labels caution against taking the product with any other stimulant.

Q: Is it safe to drive while taking Minra?

Official warnings state that Minra may cause drowsiness or dizziness. Because of the potential for these effects, official labeling advises caution when operating a motor vehicle or machinery.

Q: Why do some people say Minra didn't work for them?

Studies examining the overall effectiveness of the combination product have shown mixed or limited findings for certain individual cold symptoms. Furthermore, recent scientific discussions regarding the oral Phenylephrine component (the decongestant) have noted that data does not strongly support that the typical oral dosage is effective as a nasal decongestant. Scientific discussions suggest that uncertainty regarding the efficacy of the oral decongestant component may align with some patient reports.

Q: What should be discussed with a doctor before starting Minra?

Official labels list several medical conditions and medications that should be discussed with a healthcare professional before use. These include conditions like heart disease, high blood pressure, diabetes, thyroid disease, or glaucoma, as well as the use of certain other medicines, such as sedatives or Monoamine Oxidase Inhibitors (MAOIs).

Q: How quickly should someone expect Minra to start working?

Pharmacokinetic data from regulatory-related studies indicates that the onset of action for the Phenylephrine component is described as being within 15 to 20 minutes after administration. This data provides informational context about the timing of the product’s activity.

Q: What happens if a dose of Minra is missed?

Patient information indicates that if a regular dose is missed, it may be taken as soon as remembered. If it is nearly time for the next dose, patient instructions indicate the missed dose is skipped to continue the regular schedule.

Q: What is the risk of stopping Minra suddenly?

Minra is intended for short-term use, and regulatory information advises against using it for periods longer than seven days. The antihistamine component belongs to a class of medicines that has been examined in medical literature regarding a potential for dependence, which may raise questions about cessation. The product is intended for short-term use as described in the official label.

Q: Does Minra have a potential for dependence?

The active antihistamine component in Minra belongs to a class of medicines (first-generation antihistamines) that has been examined in regulatory-related medical literature regarding a potential for dependence. This information is derived from research literature and provides context about the pharmacological class, but it does not represent a specific warning on the official product label.

Q: Is Minra available in different strengths?

Yes, official drug information and dosage guides indicate that this fixed combination product is supplied in multiple different strengths. These varied formulations are available for both the liquid and tablet forms of the medicine.

Q: How long does Minra stay in your system after stopping treatment?

Pharmacokinetic data, which describes how the body processes the drug, indicates that the Phenylephrine component has a mean plasma half-life in the range of 2 to 3 hours after oral administration. Pharmacokinetic data provides context on the rate at which the body processes the medication.

Q: Can Minra be taken if a person has kidney problems?

Official regulatory dosage guides state that specific dose adjustment data for individuals with kidney impairment is not available. Patient information summaries generally include kidney disease as a condition that may require caution before the medication is used.

Q: Can Minra be taken if a person has liver problems?

Official regulatory dosage guides state that specific dose adjustment data for individuals with liver impairment is not available. Patient information summaries generally include liver disease as a condition that may require caution before the medication is used.

Q: What are the ingredients in Minra besides the main active component?

In addition to the two active ingredients (Brompheniramine Maleate and Phenylephrine Hydrochloride), official labeling for each formulation lists inactive ingredients, or excipients. These ingredients vary but may include substances used for coloring, flavoring, or product stability.

Q: Does Minra have any boxed warnings from regulatory agencies?

The product label does not contain a specific Boxed Warning (also known as a Black Box Warning), which is the most serious level of caution mandated by the FDA. However, the label does include prominent sections detailing severe Contraindications and Warnings, such as the absolute restriction on use with Monoamine Oxidase Inhibitors (MAOIs).

Q: Are there any ongoing clinical trials for Minra?

The National Institutes of Health (NIH) database, ClinicalTrials.gov, is the source for information on drug research. This government database lists ongoing or recently completed clinical trials registered for the combination product.

Q: Has Minra been recently approved or is it a long-established drug?

The active antihistamine component, Brompheniramine, has a long history, as it was patented in the late 1940s and came into medical use in the 1950s. This establishes the core ingredient as part of a long-established class of medicines.

Q: Where can I find the official patient information leaflet for Minra?

The official patient information, or professional label, for the product is located in government regulatory databases. You can often find the complete regulatory label, including all warnings and instructions, in the NIH DailyMed database.

How should Minra be stored and disposed of?

How to Store and Dispose of Minra (Brompheniramine Maleate and Phenylephrine Hydrochloride)

Minra must be stored according to official regulatory requirements to maintain its stability. The product requires storage at Controlled Room Temperature, which is generally defined as 15 C to 30 C (59 F to 86 F).

Storage Requirements

The medicine must be kept in its original container, tightly closed, and stored away from excessive light and moisture. Liquid forms of Minra must not be refrigerated and must not freeze to prevent product degradation. For safety, the medication must be kept securely out of the reach of children and pets.

Disposal Instructions

When disposing of unused or expired Minra, official guidelines advise against flushing it down the toilet or pouring it down a drain. If a drug take-back program is not available, the medicine should be mixed with an unappealing substance, such as dirt or used coffee grounds, placed in a sealed bag, and then discarded in the household trash.

Minra